DF 1012

Drug Profile

DF 1012

Latest Information Update: 16 Nov 2007

Price : $50

At a glance

  • Originator Dompe
  • Class Anti-inflammatories; Antiasthmatics; Antitussives; Pyrrolidines; Small molecules
  • Mechanism of Action Neuropeptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Cough

Most Recent Events

  • 20 Jun 2000 Suspended-Preclinical for Cough in Italy (PO)
  • 20 Jun 2000 Suspended-Preclinical for Asthma in Italy (PO)
  • 20 Jun 2000 Suspended-I for Cough in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top